Meet the team

The company was founded in 2011 by Frédéric Sedel, MD, PhD, a leading neurologist and neuroscientist; and Guillaume Brion, who has 25 years of experience in drug development and clinical research in the pharmaceutical industry.

Read More

Our Products

MedDay currently has molecules in development for treatment of multiple sclerosis, autism and Alzheimer’s disease.

Read More

Our Vision

MedDay addresses areas of unmet need in neurological and psychiatric diseases through the brain metabolism. This approach relies on unique clinical and pharmaceutical development expertise in the field of rare inborn errors of metabolism.

Read More

Medday SAS au capital de 11 666 €
Siège social : 26, rue des Rigoles 75 020 PARIS
R.C.S PARIS 534 957 865
Publication Director: Dr Frederic Sedel